Developer docs
API playgroundTry for free, no card

Search company profiles

Bedfont Scientific

Full company profile

uuid0007w5d

Namestring
Bedfont Scientific
Legal namestring
Bedfont Scientific Limited
Websiteurl
bedfont.com
Company typeenum
Private
Founded yearint
1976
Descriptiontext

Bedfont Scientific Limited is a UK-based Med-Tech company founded in 1976 that designs and manufactures non-invasive medical breath and gas analysis devices. Its core product portfolio centers on the NObreath FeNO device for measuring fractional exhaled nitric oxide to assess airway inflammation in asthma patients, and the coVita hydrogen/methane breath testing platform used in diagnosing gastrointestinal disorders. The company also supplies breath analysis tools used in smoking cessation programs and offers peripheral devices such as defibrillators.

Bedfont generates revenue primarily through capital-equipment hardware sales to healthcare providers — hospitals, clinics, and respiratory/GI specialists — supplemented by distribution partnerships in international markets such as Latin America (via Aerosol Medical Systems for Mexico and the broader region). The company has historically operated from a UK base in Kent, served UK and European healthcare channels directly, and pursued expansion into additional geographies through regional distributors rather than wholly owned sales infrastructure. Its go-to-market combines direct B2B sales into clinical settings with channel-partner distribution for non-core regions, supported by PR-driven brand building through awards programs and clinical advocacy.

In October 2025, Keensight Capital acquired a majority stake in Bedfont, with the stated objective of funding global expansion while retaining the existing leadership team. Subsequent activity — a new Latin America distribution deal, a clinical research partnership with University Hospital Southampton, a board addition, and CTO external recognition — points to a growth-oriented phase targeting broader FeNO adoption in UK primary care and entry into new international markets. The company remains privately held under Keensight's control with a small headcount (11-50) and no publicly disclosed revenue.

Short descriptiontext

Bedfont Scientific is a UK-based Med-Tech company founded in 1976 that designs and manufactures non-invasive breath analysis devices, including the NObreath FeNO and coVita platforms, for healthcare providers in respiratory, gastroenterology, and smoking cessation applications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHarrietsham, United Kingdom
HQ citystring
Harrietsham
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
breath analysis devices, FeNO testing equipment, medical diagnostic devices, respiratory monitoring systems, gastrointestinal breath testing
Industry3 codes
PRIMARYHLAHAGAH
Pulmonary Function Testing (PFT) & Spirometry Equipment
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAKANAE
COPD & Chronic Bronchitis Management
SECONDARYHLAHACAD
Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Medical Diagnostic Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales
TypeHardware Sales
Description

Bedfont Scientific generates revenue primarily through the sale of medical breath analysis devices including the NObreath FeNO device and coVita hydrogen breath testing device. These are capital medical equipment purchases by healthcare providers.

news-medical.net
2Distribution Partnerships
TypeHardware Sales
Description

Revenue flows through regional distribution partners like Aerosol Medical Systems who distribute Bedfont devices in Latin American markets, indicating a channel-based revenue model.

news-medical.net
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1NObreath
Description

FeNO device for measuring airway inflammation used in asthma monitoring

news-medical.net
Core offering1 text field

Bedfont Scientific designs and manufactures non-invasive medical breath analysis devices for healthcare providers. Its core offerings include the NObreath® FeNO device for measuring fractional exhaled nitric oxide to assess airway inflammation in asthma patients, and the coVita™ hydrogen breath testing platform for diagnosing gastrointestinal disorders. The company also supports smoking cessation programs through its breath analysis technology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Children using six or more blue inhalers per year are three to five times more likely to experience an asthma attack - Bedfont supports studies addressing this through FeNO testing
Product overview1 text field

Bedfont Scientific is a UK-based Med-Tech company that manufactures medical breath analysis devices. The company's product portfolio centers on the NObreath® FeNO device for measuring airway inflammation in asthma patients, and the coVita™ brand for hydrogen/methane breath testing in gastrointestinal disorder diagnosis. Bedfont also supports smoking cessation through breath analysis technology. Founded in 1976, the company recently received a majority investment from Keensight Capital and operates as a specialized manufacturer of non-invasive diagnostic breath analysis equipment.

Product and service2 records
1NObreath® FeNO Device
CategoryRespiratory diagnostic equipment
Description

A medical device for measuring fractional exhaled nitric oxide (FeNO) to assess airway inflammation in asthma patients. It supports objective asthma monitoring and diagnosis, enabling healthcare providers to detect inhaler overuse and prevent asthma attacks.

2coVita™ Hydrogen Breath Testing Device
CategoryGastrointestinal diagnostic equipment
Description

A medical breath analysis device brand under Bedfont Scientific used for diagnostic applications including hydrogen/methane breath testing to detect gastrointestinal disorders non-invasively.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-11
Description

Med-tech company Bedfont Scientific publicly supported a research study at University Hospital Southampton exploring whether enhanced asthma check-ups can reduce unnecessary reliever inhaler use among children. The study aims to develop an automated alert system for GP practices when children are over-prescribed inhalers. Bedfont called for greater investment in widespread FeNO testing adoption across UK primary care.

2Aerosol Medical Systems
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-11-04
Description

Partnership to expand access to the NObreath FeNO device for FeNO testing in Latin America, specifically including Mexico. Aerosol Medical Systems serves as the distribution partner for this territory.

news-medical.net
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Manufactures the Vivatmo FeNO device for asthma inflammation monitoring. Directly competes with NObreath in the medical breath analysis device market, particularly across European healthcare systems.

TypeDirect peer
Description

UK-based respiratory diagnostic device manufacturer with spirometry and FeNO product offerings. Direct competitor in primary care respiratory diagnostics, especially within UK and Ireland markets.

TypeBroad incumbent
Description

Global analytical instruments and laboratory equipment leader. While not a direct FeNO competitor, comparable in manufacturing analytical instrumentation for healthcare and clinical diagnostics at massive scale.

TypeDirect peer
Description

NIOX Group (formerly Aerocrine) is the leading commercial FeNO testing franchise globally with deep clinical evidence and broad geographic reach. Most directly comparable competitor in the core NObreath FeNO product category.

TypeDirect peer
Description

Specialist in hydrogen and methane breath testing instruments for gastrointestinal disorders (SIBO, lactose intolerance). Directly comparable to Bedfont's coVita hydrogen breath testing product line.

TypeEmerging player
Description

UK-based breath biopsy company developing disease-detection applications using volatile organic compound (VOC) analysis. Adjacent in breath-based diagnostics with a longer-term, biomarker-focused thesis versus Bedfont's clinical use cases.

TypeEmerging player
Description

US-based developer of the Fenom Pro FeNO device targeting clinical and primary care asthma diagnostics. Direct product overlap with NObreath FeNO in the airway inflammation monitoring category.

8Drägerwerk
TypeBroad incumbent
Description

German medical and safety technology group with broad respiratory monitoring and gas analysis portfolio including anesthesia and patient monitoring. Overlaps with Bedfont's breath/gas analysis franchise but at much larger scale and across multiple product categories.

9CIRCASSIA (now commercially focused on asthma FeNO historically)
TypeRegional player
Description

UK-based respiratory therapeutics and diagnostics company with historical FeNO presence. Comparable market positioning in UK/EU respiratory diagnostics though with different therapeutic orientation.

10Bedfont Scientific (legacy parent reference)
TypeOthers
Description

Listed as placeholder; Bedfont Scientific's own coVita subsidiary brand represents hydrogen breath testing overlap. Listed as others reference since the parent and subsidiary comparison is informational.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bedfont Scientific

Medical Diagnostic Devicesbedfont.com

Bedfont Scientific is a UK-based Med-Tech company founded in 1976 that designs and manufactures non-invasive breath analysis devices, including the NObreath FeNO and coVita platforms, for healthcare providers in respiratory, gastroenterology, and smoking cessation applications.

What Bedfont Scientific does

Bedfont Scientific Limited is a UK-based Med-Tech company founded in 1976 that designs and manufactures non-invasive medical breath and gas analysis devices. Its core product portfolio centers on the NObreath FeNO device for measuring fractional exhaled nitric oxide to assess airway inflammation in asthma patients, and the coVita hydrogen/methane breath testing platform used in diagnosing gastrointestinal disorders. The company also supplies breath analysis tools used in smoking cessation programs and offers peripheral devices such as defibrillators.

Bedfont generates revenue primarily through capital-equipment hardware sales to healthcare providers — hospitals, clinics, and respiratory/GI specialists — supplemented by distribution partnerships in international markets such as Latin America (via Aerosol Medical Systems for Mexico and the broader region). The company has historically operated from a UK base in Kent, served UK and European healthcare channels directly, and pursued expansion into additional geographies through regional distributors rather than wholly owned sales infrastructure. Its go-to-market combines direct B2B sales into clinical settings with channel-partner distribution for non-core regions, supported by PR-driven brand building through awards programs and clinical advocacy.

In October 2025, Keensight Capital acquired a majority stake in Bedfont, with the stated objective of funding global expansion while retaining the existing leadership team. Subsequent activity — a new Latin America distribution deal, a clinical research partnership with University Hospital Southampton, a board addition, and CTO external recognition — points to a growth-oriented phase targeting broader FeNO adoption in UK primary care and entry into new international markets. The company remains privately held under Keensight's control with a small headcount (11-50) and no publicly disclosed revenue.

Bedfont Scientific firmographics

Firmographics
Name
Bedfont Scientific
Legal name
Bedfont Scientific Limited
Website
https://bedfont.com
Company type
Private
Founded year
1976
Operating status
Operating
Headcount range
51–100 employees
Short description
Bedfont Scientific is a UK-based Med-Tech company founded in 1976 that designs and manufactures non-invasive breath analysis devices, including the NObreath FeNO and coVita platforms, for healthcare providers in respiratory, gastroenterology, and smoking cessation applications.
Ownership category
akta.pro rank

Bedfont Scientific industry classification

Industry
Product category
Medical Diagnostic Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAHAGAH
Pulmonary Function Testing (PFT) & Spirometry Equipment
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAKANAE
COPD & Chronic Bronchitis Management
SECONDARYHLAHACAD
Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Breath analysis devices
  • FeNO testing equipment
  • Medical diagnostic devices
  • Respiratory monitoring systems
  • Gastrointestinal breath testing

Where Bedfont Scientific is headquartered

Location

Headquarters

HQ city
Harrietsham
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Bedfont Scientific business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. Medical Device Sales: Bedfont Scientific generates revenue primarily through the sale of medical breath analysis devices including the NObreath FeNO device and coVita hydrogen breath testing device. These are capital medical equipment purchases by healthcare providers.
  2. Distribution Partnerships: Revenue flows through regional distribution partners like Aerosol Medical Systems who distribute Bedfont devices in Latin American markets, indicating a channel-based revenue model.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Bedfont Scientific product offering

Product offering

Core offering

Bedfont Scientific designs and manufactures non-invasive medical breath analysis devices for healthcare providers. Its core offerings include the NObreath® FeNO device for measuring fractional exhaled nitric oxide to assess airway inflammation in asthma patients, and the coVita™ hydrogen breath testing platform for diagnosing gastrointestinal disorders. The company also supports smoking cessation programs through its breath analysis technology.

Product overview

Bedfont Scientific is a UK-based Med-Tech company that manufactures medical breath analysis devices. The company's product portfolio centers on the NObreath® FeNO device for measuring airway inflammation in asthma patients, and the coVita™ brand for hydrogen/methane breath testing in gastrointestinal disorder diagnosis. Bedfont also supports smoking cessation through breath analysis technology. Founded in 1976, the company recently received a majority investment from Keensight Capital and operates as a specialized manufacturer of non-invasive diagnostic breath analysis equipment.

Differentiator

Problem solved

Functional benefit

Brands

  • NObreath: FeNO device for measuring airway inflammation used in asthma monitoring

Products and services

  • NObreath® FeNO Device A medical device for measuring fractional exhaled nitric oxide (FeNO) to assess airway inflammation in asthma patients. It supports objective asthma monitoring and diagnosis, enabling healthcare providers to detect inhaler overuse and prevent asthma attacks.
  • coVita™ Hydrogen Breath Testing Device A medical breath analysis device brand under Bedfont Scientific used for diagnostic applications including hydrogen/methane breath testing to detect gastrointestinal disorders non-invasively.

Quantifiable outcome

  • Children using six or more blue inhalers per year are three to five times more likely to experience an asthma attack - Bedfont supports studies addressing this through FeNO testing

Companies that use Bedfont Scientific

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Bedfont Scientific technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Bedfont Scientific partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • University Hospital SouthamptoncoreStrategic or Co-development Partner · 11 March 2026Med-tech company Bedfont Scientific publicly supported a research study at University Hospital Southampton exploring whether enhanced asthma check-ups can reduce unnecessary reliever inhaler use among children. The study aims to develop an automated alert system for GP practices when children are over-prescribed inhalers. Bedfont called for greater investment in widespread FeNO testing adoption across UK primary care.
  • Aerosol Medical SystemscoreChannel Partner/ Reseller/ Distributor · 4 November 2025Partnership to expand access to the NObreath FeNO device for FeNO testing in Latin America, specifically including Mexico. Aerosol Medical Systems serves as the distribution partner for this territory.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Bedfont Scientific competitors and assessment

Company assessment

Direct peers

  • Bosch Healthcare Solutions: Manufactures the Vivatmo FeNO device for asthma inflammation monitoring. Directly competes with NObreath in the medical breath analysis device market, particularly across European healthcare systems.
  • Vitalograph: UK-based respiratory diagnostic device manufacturer with spirometry and FeNO product offerings. Direct competitor in primary care respiratory diagnostics, especially within UK and Ireland markets.
  • NIOX Group: NIOX Group (formerly Aerocrine) is the leading commercial FeNO testing franchise globally with deep clinical evidence and broad geographic reach. Most directly comparable competitor in the core NObreath FeNO product category.
  • QuinTron Instrument Company: Specialist in hydrogen and methane breath testing instruments for gastrointestinal disorders (SIBO, lactose intolerance). Directly comparable to Bedfont's coVita hydrogen breath testing product line.

Broad incumbents

  • Thermo Fisher Scientific: Global analytical instruments and laboratory equipment leader. While not a direct FeNO competitor, comparable in manufacturing analytical instrumentation for healthcare and clinical diagnostics at massive scale.
  • Drägerwerk: German medical and safety technology group with broad respiratory monitoring and gas analysis portfolio including anesthesia and patient monitoring. Overlaps with Bedfont's breath/gas analysis franchise but at much larger scale and across multiple product categories.

Emerging players

  • Owlstone Medical: UK-based breath biopsy company developing disease-detection applications using volatile organic compound (VOC) analysis. Adjacent in breath-based diagnostics with a longer-term, biomarker-focused thesis versus Bedfont's clinical use cases.
  • Spirosure: US-based developer of the Fenom Pro FeNO device targeting clinical and primary care asthma diagnostics. Direct product overlap with NObreath FeNO in the airway inflammation monitoring category.

Regional players

  • CIRCASSIA (now commercially focused on asthma FeNO historically): UK-based respiratory therapeutics and diagnostics company with historical FeNO presence. Comparable market positioning in UK/EU respiratory diagnostics though with different therapeutic orientation.

Others

  • Bedfont Scientific (legacy parent reference): Listed as placeholder; Bedfont Scientific's own coVita subsidiary brand represents hydrogen breath testing overlap. Listed as others reference since the parent and subsidiary comparison is informational.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Bedfont Scientific social profiles

Digital presence

Bedfont Scientific financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bedfont Scientific leadership team

Management profile

Number of profiles

Profiles5 records

Bedfont Scientific subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Bedfont Scientific funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bedfont Scientific M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bedfont Scientific

What does Bedfont Scientific do?

Bedfont Scientific designs and manufactures non-invasive medical breath analysis devices for healthcare providers. Its core offerings include the NObreath® FeNO device for measuring fractional exhaled nitric oxide to assess airway inflammation in asthma patients, and the coVita™ hydrogen breath testing platform for diagnosing gastrointestinal disorders. The company also supports smoking cessation programs through its breath analysis technology.

Is Bedfont Scientific a public or private company?

Bedfont Scientific is a private company. It is classified as venture growth investor backed and is currently operating.

When was Bedfont Scientific founded?

Bedfont Scientific was founded in 1976. It employs 51 to 100 people.

Where is Bedfont Scientific based?

Bedfont Scientific is headquartered in Harrietsham, United Kingdom, in the Europe region.

How does Bedfont Scientific make money?

Two revenue lines are on record. Medical Device Sales are the primary driver. The others are distribution Partnerships.

Who are Bedfont Scientific's main competitors?

Direct peers on record are Bosch Healthcare Solutions, Vitalograph, NIOX Group and QuinTron Instrument Company. Broad incumbents are Thermo Fisher Scientific and Drägerwerk. Emerging players are Owlstone Medical and Spirosure. CIRCASSIA (now commercially focused on asthma FeNO historically) is listed as a regional player. Bedfont Scientific (legacy parent reference) is listed as an others.

Does Bedfont Scientific have an API?

No public API is recorded for Bedfont Scientific.

What industry is Bedfont Scientific in?

Bedfont Scientific's product category is Medical Diagnostic Devices. Its primary akta.pro industry code is HLAHAGAH, Pulmonary Function Testing (PFT) & Spirometry Equipment, with a secondary code of HLAKANAE, COPD & Chronic Bronchitis Management. Its NAICS code is 334510 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PRLogBedfont® Scientific strengthens its commitment to respiratory clinical researchBedfont Scientific is focusing on supporting respiratory clinical research, debuting at the 9th annual Outsourcing in Clinical Trials DACH conference in Basel. Its NObreath FeNO device has aided asthma diagnosis for over 15 years, providing accurate measurements for long-term studies. The company will demonstrate the device at stand 10b.InsidermediaBreath testing medtech acquires longtime US distributorBedfont Scientific, a Kent-based breath analysis firm, acquired coVita, a Texas-based medical device manufacturer that has served as its US distributor for over 16 years. The deal aims to strengthen Bedfont's US presence with devices like the NObreath FeNO, and coVita's leadership and team will remain unchanged.News-MedicalBedfont® Scientific one step closer to improving smoking cessation in Latin AmericaBedfont Scientific registered its Smokerlyzer CO monitoring devices with Medicah S.A.S. in Colombia to support smoking cessation. The devices measure exhaled carbon monoxide in ppm, providing clinicians with an objective measure to aid behavior change. The partnership expands respiratory diagnostics in the region.News-MedicalBedfont® Scientific Limited recognized among Investec’s selected investments for 2025Bedfont, a UK-based breath analysis technology company, was named among Investec Direct Lending's selected investments for 2025 following a majority investment from Keensight Capital. The inclusion appears in Investec's Sustainability Report, citing the company's long-term growth strategy and responsible innovation. Bedfont has operated for over 50 years and plans international expansion.News-MedicalBedfont® brings respiratory monitoring solutions to ERS with a focus on clinical researchBedfont® Scientific Limited is attending the European Respiratory Society (ERS) Congress in Barcelona from September 5th to 9th to showcase its innovative respiratory monitoring technology, including the NObreath® FeNO device and Smokerlyzer® range. The congress is the largest international meeting dedicated to respiratory medicine, expected to attract about 20,000 professionals from around the world, and serves as a platform to promote collaboration in respiratory care. Bedfont® aims to strengthen its commitment to clinical research during this significant event.News-MedicalAsthma care is evolving. How FeNO testing is changing the way we treat asthmaBedfont® Scientific Limited announced that over 1 million people with asthma in the UK are now using combination inhalers following 2024 joint guidelines from NICE, BTS, and SIGN, with NObreath® FeNO device sales exceeding 1,240 units since the November 2024 update. The company highlighted that FeNO testing enables clinicians to objectively measure airway inflammation and tailor anti-inflammatory treatment, supporting a shift toward prevention-focused asthma care. Bedfont works with its UK distributor Intermedical UK, which launched the NObreath® 3000 campaign and achieved a milestone of 3,000 total NObreath® sales in the UK.PRLogBedfont® Scientific recognised for global growth with SEHTA Awards export shortlistBedfont Scientific was shortlisted for the SEHTA Healthcare Business Awards Export Achievement award. The breath analysis company reports over 59% of its annual turnover comes from export sales, with a global network of over 100 distributors. The awards ceremony is scheduled for 26 May at Scale Space, Imperial College London.PRLogShaping the future of asthma management with the NObreath® at ATS 2026Bedfont will showcase its NObreath FeNO device at the ATS 2026 conference in Orlando, Florida, from May 15-20. The device has been improving asthma care for over 15 years by measuring airway inflammation non-invasively. Bedfont's team will be at booth 1236, with a talk on FeNO in practice.News-MedicalStudy on inhaler overuse highlights urgent need for better objective asthma monitoringA new study at University Hospital Southampton is exploring whether enhanced asthma check-ups can reduce unnecessary reliever inhaler use among children, with research finding that children using six or more blue inhalers per year are three to five times more likely to experience an asthma attack. The study aims to develop an automated alert system that notifies general practitioners when a child has been over-prescribed inhalers, prompting an immediate review. Med-tech company Bedfont Scientific Limited, which manufactures the NObreath FeNO device for measuring airway inflammation, has publicly supported the study and called for greater investment in widespread FeNO testing adoption across UK primary care.News-MedicalGiving opportunity, gaining innovation: Women driving the future of Med-TechBedfont® Scientific Limited, a UK-based Med-Tech company specializing in medical breath analysis devices, is marking International Women's Day 2026 by highlighting its gender diversity achievements, with women comprising 50% of its workforce and nearly half of its 18 managerial positions. The company's Chief Operating Director Natasha Smith emphasized that inclusion drives both performance and progress in the industry. The article notes that while Switzerland leads in Med-Tech with women holding 40% of industry roles, women occupy only 24.4% of leadership positions across Europe's 78 largest medical device companies.